Program
Atropine
Also written as “Atropine Sulfate”, “Low dose atropine sulfate eye drops” and “atropine sulfate”.
Its studies are mostly in Myopia · Myopia, Degenerative · Insulin Resistance · Rhinitis, Allergic, Seasonal, led by 14 companies.
Drug pageAtropine: every studyMany companies study it; this page follows only the 17 they lead. All 125 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hai Yen Eye Careits history only | 20 open or running | phase 1since Sep 27, 2018 | Sep 27, 2018 | none ahead |
| Laboratorios Sophia S.A de C.V.its history only | 20 open or running | phase 1since Mar 23, 2022 | Mar 23, 2022 | none ahead |
| Zhaoke (Guangzhou) Ophthalmology Pharmaceuticalits history only | 22 open or running | phase 3since Jan 5, 2024 | Jan 5, 2024 | none ahead |
| Cloudbreak Therapeuticsits history only | 10 open or running | phase 2since May 5, 2021 | May 5, 2021 | none ahead |
| Eyenoviaits history only | 10 open or running | phase 3since May 7, 2019 | May 7, 2019 | none ahead |
| IDB VisionCare SDN BHDits history only | 11 open or running | phase 3since Sep 16, 2025 | Sep 16, 2025 | Sep 2027phase 3 · NCT07329777 |
| Kubota Pharmaceuticalits history only | 11 open or running | no phasesince Aug 26, 2023 | Aug 26, 2023 | none ahead |
| Magna Pharmaceuticalsits history only | 10 open or running | phase 2since Feb 26, 2014 | Feb 26, 2014 | none ahead |
| MicroDose Defense Productsits history only | 10 open or running | phase 1since Jul 22, 2009 | Jul 22, 2009 | none ahead |
| Ocumension Therapeutics (Suzhou)its history only | 10 open or running | phase 3since Nov 18, 2024 | Nov 18, 2024 | none ahead |
| Ocus Innovation Irelandits history only | 11 open or running | phase 3since May 23, 2025 | May 23, 2025 | Dec 31, 2027phase 3 · NCT07028827 |
| SciMarits history only | 10 open or running | no phasesince Oct 29, 2020 | Oct 29, 2020 | none ahead |
| Sydnexisits history only | 10 open or running | phase 3since Apr 12, 2019 | Apr 12, 2019 | none ahead |
| Zhaoke (Hong Kong) Ophthalmology Pharmaceuticalits history only | 11 open or running | phase 1since Apr 23, 2023 | Apr 23, 2023 | none ahead |
- Named in jiangsu hengrui medicine’s own pipeline as
Atropine eye drops
, phase 4, as of Jul 31, 2026 (source).
Also a collaborator on its studies: Euromed Pharma Services SRL, Novotech (Australia) Pty, Source Nutraceutical and Brien Holden Vision.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Jul 22, 2009.
- Sep 27, 2018Hai Yen Eye Care’s first study: phase 1 study in MyopiaNew to Hai Yen Eye CareHai Yen Eye Care · NCT03690414 · 52 enrolled · Vietnam
- Oct 5, 2018Phase 1 study in MyopiaHai Yen Eye Care · NCT03699423 · 58 enrolled · Vietnam
- Apr 12, 2019Sydnexis’s first study: phase 3 study in MyopiaNew to SydnexisSydnexis · NCT03918915 · 852 enrolled · United States, Austria, Slovakia
- May 7, 2019Eyenovia’s first study: phase 3 study in MyopiaNew to EyenoviaEyenovia · NCT03942419 · 438 enrolled · United States
- Oct 29, 2020SciMar’s first study: no phase study in Insulin ResistanceNew to SciMarSciMar · NCT04625088 · 24 enrolled · Canada
- May 5, 2021Cloudbreak Therapeutics’ first study: phase 2 study in Myopia, DegenerativeNew to Cloudbreak TherapeuticsCloudbreak Therapeutics · NCT05372991 · 84 enrolled · Australia
- Mar 23, 2022Laboratorios Sophia S.A de C.V.’s first study: phase 1 study in MyopiaNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT05470881 · 29 enrolled · Mexico
- Jul 28, 2022Phase 1 study in MyopiaLaboratorios Sophia S.A de C.V. · NCT05481489
- Apr 23, 2023Zhaoke (Hong Kong) Ophthalmology Pharmaceutical’s first study: phase 1 study in PharmacokineticsNew to Zhaoke (Hong Kong) Ophthalmology PharmaceuticalZhaoke (Hong Kong) Ophthalmology Pharmaceutical · NCT05855018 · 30 planned · China
- Aug 26, 2023Kubota Pharmaceutical’s first study: no phase study in MyopiaNew to Kubota PharmaceuticalKubota Pharmaceutical · NCT06034379 · 45 planned · Taiwan
- Jan 5, 2024Zhaoke (Guangzhou) Ophthalmology Pharmaceutical’s first studies: 2 phase 3 studies in MyopiaNew to Zhaoke (Guangzhou) Ophthalmology PharmaceuticalZhaoke (Guangzhou) Ophthalmology Pharmaceutical · NCT06209281, NCT06209320
- Nov 18, 2024Ocumension Therapeutics (Suzhou)’s first study: phase 3 study in MyopiaNew to Ocumension Therapeutics (Suzhou)Ocumension Therapeutics (Suzhou) · NCT06697522 · 148 enrolled · China
- May 23, 2025Ocus Innovation Ireland’s first study: phase 3 study in MyopiaNew to Ocus Innovation IrelandOcus Innovation Ireland · NCT07028827 · 234 planned · Albania, Italy, Poland and more
- Sep 16, 2025IDB VisionCare SDN BHD’s first study: phase 3 study in Myopia ProgressionNew to IDB VisionCare SDN BHDIDB VisionCare SDN BHD · NCT07329777 · 144 planned · Malaysia
Ahead
- Sep 2027Primary completion: phase 3 study in Myopia ProgressionIDB VisionCare SDN BHD · NCT07329777
- Dec 31, 2027Primary completion: phase 3 study in MyopiaOcus Innovation Ireland · NCT07028827
TargetBeta
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M1 antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07329777Myopia Progression · Malaysia | 3 | Recruiting | IDB VisionCare SDN BHD | Sep 2027 | 144 |
| NCT07028827Myopia · Albania, Italy, Poland and more | 3 | Recruiting | Ocus Innovation Ireland | Dec 31, 2027 | 234 |
| NCT06697522Myopia · China | 3 | Completed | Ocumension Therapeutics (Suzhou) | Oct 6, 2023 | 148 |
| NCT06209320Myopia · China | 3 | Active, not recruiting | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | Mar 21, 2025 | 777 |
| NCT06209281Myopia · China | 3 | Active, not recruiting | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | Aug 20, 2023 | 526 |
| NCT06034379Myopia · Taiwan | – | Recruiting | Kubota Pharmaceutical | Dec 2025 | 45 |
| NCT05855018Pharmacokinetics · China | 1 | Recruiting | Zhaoke (Hong Kong) Ophthalmology Pharmaceutical | Jun 2023 | 30 |
| NCT05481489Myopia | 1 | Withdrawn | Laboratorios Sophia S.A de C.V. | Mar 31, 2023 | 0 |
| NCT05470881Myopia · Mexico | 1 | Completed | Laboratorios Sophia S.A de C.V. | Dec 26, 2022 | 29 |
| NCT05372991Myopia, Degenerative · Australia | 2 | Completed | Cloudbreak Therapeutics | Jan 18, 2023 | 84 |
| NCT04625088Insulin Resistance · Canada | – | Completed | SciMar | Aug 6, 2021 | 24 |
| NCT03942419Myopia · United States | 3 | Terminated | Eyenovia | Oct 31, 2024 | 438 |
| NCT03918915Myopia · United States, Austria, Slovakia | 3 | Completed | Sydnexis | May 2, 2024 | 852 |
| NCT03699423Myopia · Vietnam | 1 | Completed | Hai Yen Eye Care | Apr 30, 2018 | 58 |
| NCT03690414Myopia · Vietnam | 1 | Completed | Hai Yen Eye Care | Feb 2, 2019 | 52 |
| NCT02082054Rhinitis, Allergic, Seasonal · United States | 2 | UNKNOWN | Magna Pharmaceuticals | May 2014 | 125 |
| NCT00947596Organophosphate Poisoning · United States | 1 | Completed | MicroDose Defense Products | Jul 2010 | 18 |
How it is read
Names in the registry
- “Atropine Sulfate”, 3 entries
- “Low dose atropine sulfate eye drops”, 3 entries
- “atropine sulfate”, 2 entries
- “SYD-101 0.01%”, 1 entry
- “SYD-101 0.03%”, 1 entry
Conditions, from the studies’ own filings
- Myopia, 12 studies
- Myopia, Degenerative, 1 study
- Insulin Resistance, 1 study
- Rhinitis, Allergic, Seasonal, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.